CY1120543T1 - Σταθεροποιητες τρανσθυρετινης και χρηση αυτων για αναστολη αμυλοειδωσης τρανσθυρετινης και αλληλεπιδρασεων πρωτεϊνης-πρωτεϊνης - Google Patents

Σταθεροποιητες τρανσθυρετινης και χρηση αυτων για αναστολη αμυλοειδωσης τρανσθυρετινης και αλληλεπιδρασεων πρωτεϊνης-πρωτεϊνης

Info

Publication number
CY1120543T1
CY1120543T1 CY20181100823T CY181100823T CY1120543T1 CY 1120543 T1 CY1120543 T1 CY 1120543T1 CY 20181100823 T CY20181100823 T CY 20181100823T CY 181100823 T CY181100823 T CY 181100823T CY 1120543 T1 CY1120543 T1 CY 1120543T1
Authority
CY
Cyprus
Prior art keywords
protein
transythrine
transythretine
stabilizers
style
Prior art date
Application number
CY20181100823T
Other languages
English (en)
Inventor
Isabella A. Graef
Mamoun M. ALHAMADSHEH
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of CY1120543T1 publication Critical patent/CY1120543T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Αποκαλυπτόμενες στο παρόν είναι ενώσεις και συνθέσεις αυτών που βρίσκουν χρήση στην αυξανόμενη σταθερότητα πρωτεϊνών, ιδιαιτέρως πρωτεϊνών που τείνουν να αναδιπλώνονται εσφαλμένα και να σχηματίζουν συσσωματώματα. Επίσης παρεχόμενες στο παρόν είναι μέθοδοι για χρήση αυτών των ενώσεων και συνθέσεων για αύξηση σταθερότητας πρωτεϊνών και με τον τρόπο αυτό μείωση σχηματισμού συσσωματώματος με αυτές τις πρωτεΐνες. Επίσης αποκαλυπτόμενες στο παρόν είναι ετεροδιλειτουργικές ενώσεις που περιλαμβάνουν ένωση σύνδεσης TTR συνδεδεμένη προς μία χαρακτηριστική ομάδα στοχοθέτησης μέσω συνδέτη, για χρήση στη διάσπαση PPIs μιας πρωτεΐνης στόχου.
CY20181100823T 2012-12-21 2018-08-07 Σταθεροποιητες τρανσθυρετινης και χρηση αυτων για αναστολη αμυλοειδωσης τρανσθυρετινης και αλληλεπιδρασεων πρωτεϊνης-πρωτεϊνης CY1120543T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745089P 2012-12-21 2012-12-21
US13/830,731 US9169214B2 (en) 2012-12-21 2013-03-14 Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
PCT/US2013/076213 WO2014100227A1 (en) 2012-12-21 2013-12-18 Transthyretin stabilizers and their use for inhibiting transthyretin amyloidosis and protein-protein interactions

Publications (1)

Publication Number Publication Date
CY1120543T1 true CY1120543T1 (el) 2019-07-10

Family

ID=50975335

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100823T CY1120543T1 (el) 2012-12-21 2018-08-07 Σταθεροποιητες τρανσθυρετινης και χρηση αυτων για αναστολη αμυλοειδωσης τρανσθυρετινης και αλληλεπιδρασεων πρωτεϊνης-πρωτεϊνης

Country Status (14)

Country Link
US (7) US9169214B2 (el)
EP (1) EP2934514B1 (el)
JP (1) JP6333289B2 (el)
CY (1) CY1120543T1 (el)
DK (1) DK2934514T3 (el)
ES (1) ES2683994T3 (el)
HR (1) HRP20181268T1 (el)
HU (1) HUE038853T2 (el)
LT (1) LT2934514T (el)
PL (1) PL2934514T3 (el)
PT (1) PT2934514T (el)
RS (1) RS57572B1 (el)
SI (1) SI2934514T1 (el)
WO (1) WO2014100227A1 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102333761B (zh) 2009-01-28 2017-12-19 卡鲁斯治疗有限公司 Scriptaid电子等排体及其在治疗中的用途
US8877795B2 (en) 2010-05-07 2014-11-04 The Board Of Trustees Of The Leland Stanford Junior University Identification of stabilizers of multimeric proteins
CA2888861A1 (en) 2012-11-07 2014-05-15 Karus Therapeutics Ltd Novel histone deacetylase inhibitors and their use in therapy
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
PT2994465T (pt) 2013-05-10 2018-10-25 Karus Therapeutics Ltd Novos inibidores de histona desacetilase
EP3179857B1 (en) * 2014-08-14 2021-09-08 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
IL268683B2 (en) * 2017-02-17 2023-04-01 Eidos Therapeutics Inc Processes for the preparation of ag-10, its intermediates and salts
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
MA52137A (fr) 2018-03-23 2021-01-27 Eidos Therapeutics Inc Méthodes de traitement de l'amylose ttr à l'aide d'ag10
UA128256C2 (uk) * 2018-08-17 2024-05-22 Ейдос Терапьютікс, Інк. Препарати ag10
US20220071965A1 (en) 2018-12-20 2022-03-10 Pfizer Inc. Pharmaceutical Compositions and Methods Comprising A Combination of a Benzoxazole Transthyretin Stabilizer and an Additional Therapeutic Agent
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
CN114173771A (zh) * 2019-05-31 2022-03-11 普莱克斯医药公司 用于治疗眼部蛋白质聚集疾病的药理学试剂
CN115551886A (zh) 2020-05-12 2022-12-30 生物控股有限公司 用于ttr淀粉样变性的联合疗法
WO2022112919A1 (en) 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds
US20240238426A1 (en) * 2021-03-04 2024-07-18 The Scripps Research Institute Protein acylation modulation by heterobifunctional molecules
WO2023009612A1 (en) 2021-07-28 2023-02-02 Protego Biopharma, Inc. Acoramidis (3-(3-(3,5-dimethyl-1h-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid) derivatives for stabilizing transthyretin (tts) and inhibiting tts misfolding for the treatment of e.g. peripheral ttr amyloidosis
WO2023052652A1 (en) 2021-10-01 2023-04-06 Sandoz Ag Crystalline form of acoramidis hydrochloride

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4171365A (en) * 1977-08-05 1979-10-16 Sterling Drug Inc. Antiviral aryloxyalkylpyrazoles
US4261928A (en) * 1977-08-05 1981-04-14 Sterling Drug Inc. 2-Benzoyl-8-(2-chloro-4-methoxyphenoxy)-1-phenyl-1-octanone
US4232161A (en) * 1979-10-24 1980-11-04 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-(2-pyridinyl)-1H-pyrazole
US4234725A (en) * 1979-10-24 1980-11-18 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-[4-(4-morpholinyl)-1-oxobutyl]-1H-pyrazole
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
SU1824398A1 (ru) * 1991-04-29 1993-06-30 Bakinskij G Uni Im M E Rasulza 3,4,5-замещенные пиразолы, обладающие антигрибковой активностью 2
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
NZ334914A (en) 1996-10-01 2000-09-29 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture using a phase seperation-coacervation technique
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
AU5727798A (en) 1996-12-23 1998-07-17 Texas A & M University, The Anti-amyloidogenic agents
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
KR100719273B1 (ko) 1997-10-28 2007-05-18 반도 카가쿠 가부시키가이샤 피부 패치 시트 및 그것을 위한 베이스 시트의 제조 방법
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
AU4180900A (en) * 1999-04-02 2000-10-23 Du Pont Pharmaceuticals Company Novel amide derivatives as inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
WO2002059621A2 (en) 2001-01-24 2002-08-01 Bayer Corporation Regulation of transthyretin to treat obesity
EP1389194A2 (en) * 2001-04-27 2004-02-18 Vertex Pharmaceuticals Incorporated Inhibitors of bace
CN1602291B (zh) * 2001-11-16 2010-05-12 富山化学工业株式会社 新二苯甲酮衍生物或其盐
WO2003099793A1 (en) * 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited 1,2-azole derivatives with hypoglycemic and hypolipidemic activity
CN101413143B (zh) 2002-12-19 2013-09-18 斯克里普斯研究学院 稳定甲状腺素运载蛋白和抑制甲状腺素运载蛋白错折叠的组合物和方法
US7396850B2 (en) * 2003-01-06 2008-07-08 Eli Lilly And Company Pyrazole derivative as PPAR modulator
ITBO20030453A1 (it) 2003-07-29 2005-01-30 Pulsar Srl Dispositivo di convogliamento senza accumulo di residui.
JP2007284350A (ja) * 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
WO2008016811A2 (en) * 2006-07-31 2008-02-07 Neurogen Corporation Aminopiperidines and realted compounds
CN101687790B (zh) * 2007-05-25 2015-02-11 Abbvie公司 作为代谢型谷氨酸受体2(mglu2受体)的正向调节剂的杂环化合物
WO2009148961A2 (en) * 2008-05-29 2009-12-10 Wisconsin Alumni Research Foundation Drugs to prevent hpv infection
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
US8048887B2 (en) * 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7994171B2 (en) * 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
JP5743897B2 (ja) * 2008-11-20 2015-07-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 化合物
JP5099731B1 (ja) * 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
AR079022A1 (es) * 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
US8877795B2 (en) * 2010-05-07 2014-11-04 The Board Of Trustees Of The Leland Stanford Junior University Identification of stabilizers of multimeric proteins
CN106220618B (zh) * 2010-12-16 2019-04-26 阿勒根公司 作为趋化因子受体调节剂的硫衍生物
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions

Also Published As

Publication number Publication date
EP2934514A1 (en) 2015-10-28
PL2934514T3 (pl) 2018-12-31
ES2683994T3 (es) 2018-10-01
WO2014100227A1 (en) 2014-06-26
US20210260034A1 (en) 2021-08-26
US10842777B2 (en) 2020-11-24
DK2934514T3 (en) 2018-08-20
RS57572B1 (sr) 2018-11-30
US9913826B2 (en) 2018-03-13
LT2934514T (lt) 2018-09-10
EP2934514A4 (en) 2016-06-08
US9169214B2 (en) 2015-10-27
US20230390246A1 (en) 2023-12-07
JP6333289B2 (ja) 2018-05-30
PT2934514T (pt) 2018-10-16
US20170340608A1 (en) 2017-11-30
EP2934514B1 (en) 2018-05-16
HUE038853T2 (hu) 2018-12-28
JP2016504338A (ja) 2016-02-12
SI2934514T1 (sl) 2018-10-30
US20200093797A1 (en) 2020-03-26
US20140179751A1 (en) 2014-06-26
US20160081984A1 (en) 2016-03-24
US9642838B2 (en) 2017-05-09
US10398681B2 (en) 2019-09-03
US20190000805A1 (en) 2019-01-03
HRP20181268T1 (hr) 2018-10-05

Similar Documents

Publication Publication Date Title
CY1120543T1 (el) Σταθεροποιητες τρανσθυρετινης και χρηση αυτων για αναστολη αμυλοειδωσης τρανσθυρετινης και αλληλεπιδρασεων πρωτεϊνης-πρωτεϊνης
CY1123419T1 (el) Αντιδραστηρια sirp-αλφα υψηλης συγγενειας
CY1124522T1 (el) Ενωσεις και μεθοδοι για ρυθμιση της εκφρασης πρωτεϊνης κινασης μυοτονικης δυστροφιας (dmpk)
CY1125392T1 (el) Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων
DOP2021000005A (es) Proteínas de unión a pd1 y/o lag3
CY1123788T1 (el) Αντισωματα αντι-ακτιβινης α και χρησεις αυτων
CY1124028T1 (el) Συνθεσεις και μεθοδοι για τα αντισωματα που στοχευουν την ερο
CY1121389T1 (el) Αντισωματα που δεσμευονται ειδικα με την α-τοξινη toy staphylococcus aureus και μεθοδοι χρησης
CY1120471T1 (el) Αντισωματα κατα του cd70
ECSP18030970A (es) Proteínas de unión a pd-1 y métodos para usarlas
CY1122720T1 (el) Υποδοχεις τ κυτταρων που αναγνωριζουν περιορισμενη μαgε-α3 μηc ταξης ii
CY1123609T1 (el) Βελτιστοποιηση αντισωματων που δεσμευουν το γονιδιο-3 ενεργοποιησης λεμφοκυτταρων (lag-3), και χρησεις εξ΄ αυτων
CY1126149T1 (el) Ανασυνδυασμενα ιικα σωματιδια με τροποποιημενο τροπισμο και χρησεις αυτων για τη στοχευμενη εισαγωγη γενετικου υλικου σε ανθρωπινα κυτταρα
EA201491644A1 (ru) Фармацевтические композиции
CY1121934T1 (el) Αντισωματα anti-fcrn
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
CY1118339T1 (el) Διειδικα μορια προσδεσης που προσδενονται στον vegf και στην ang2
CY1121964T1 (el) Αντισωματα εναντιον toy csf-1r
UY35407A (es) ?PROTEÍNAS DE FUSIÓN COMPRENDIENDO PORCIONES PDGF y VEGF DE UNIÓN Y MÉTODOS PARA SU USO?.
CY1124896T1 (el) Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων
UA117364C2 (uk) Похідні аматоксину
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
AR099288A1 (es) Proteínas de fusión de interleucina-10
BR112016012358A2 (pt) peptídios terapêuticos
CO6630164A2 (es) Proteinas que se unen al tnf-a